首页> 外文期刊>Retina >The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment.
【24h】

The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment.

机译:纤溶酶原-尿激酶联合诱导玻璃体后脱离的功效。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To investigate the toxicity of intravitreal plasminogen, urokinase, and their combination, and to evaluate their efficacy in the production of posterior vitreous detachment (PVD) in the rabbit eye. METHODS: Fifty-six albino New Zealand rabbits were examined before and after injection using the indirect ophthalmoscope, slit-lamp biomicroscopy, and electroretinography. Various concentrations of urokinase or recombinant plasminogen or a combination were injected intravitreally into the right eyes of four rabbits for each concentration. The left eyes of the animals served as controls and received 0.1 mL balanced salt solution. Group 1 was injected with pure urokinase (1,000, 5,000, or 10,000 IU); Group 2 with recombinant plasminogen (0.1, 0.4, 1.0, 2.0, 4.0, 8.0, or 16.0 caseinolytic units [CU]); and Group 3 with a combination of 1,000 IU urokinase (highest nontoxic dose) and nontoxic concentrations of plasminogen (0.1, 0.4, 1.0, or 2.0 CU). The animals were killed and the eyes enucleated 15 days after injection. Electron and light microscopy were performed. RESULTS: A concentration of 1,000 IU of urokinase was found to be nontoxic to the retina. Plasminogen concentrations of 2.0 CU or less did not produce retinal toxicity, whereas 4.0, 8.0, and 16.0 CU of plasminogen caused minimal-to-severe inflammatory response in the vitreous without histologic or electroretinographic changes. Neither plasminogen nor urokinase alone was successful in producing PVD. The combination of 1,000 IU of urokinase and 1.0 to 2.0 CU of plasminogen was effective without causing retinal toxicity. CONCLUSION: Posterior vitreous detachment can be produced in the rabbit eye using a combination of plasminogen and urokinase.
机译:目的:研究玻璃体内纤溶酶原,尿激酶及其组合的毒性,并评估其在兔眼玻璃体后脱离(PVD)产生中的功效。方法:使用间接检眼镜,裂隙灯生物显微镜和视网膜电图检查了56只新西兰白化兔的注射前后。将每种浓度的各种浓度的尿激酶或重组纤溶酶原或其组合物玻璃体内注射入四只兔子的右眼。动物的左眼用作对照并接​​受0.1mL平衡盐溶液。第1组注射纯的尿激酶(1,000、5,000或10,000 IU);第2组具有重组纤溶酶原(0.1、0.4、1.0、2.0、4.0、8.0或16.0酪蛋白溶解单位[CU]);和第3组,分别使用1,000 IU尿激酶(最高无毒剂量)和无毒浓度的纤溶酶原(0.1、0.4、1.0或2.0 CU)。注射后15天将动物处死并摘除眼睛。进行电子和光学显微镜检查。结果:发现浓度为1,000 IU的尿激酶对视网膜无毒。纤溶酶原浓度低于或等于2.0 CU不会产生视网膜毒性,而纤溶酶原的4.0、8.0和16.0 CU引起的玻璃体炎症反应最小至严重,而无组织学或视网膜电图改变。纤溶酶原和尿激酶都不单独成功产生PVD。 1,000 IU尿激酶和1.0到2.0 CU纤溶酶原的组合是有效的,不会引起视网膜毒性。结论:结合使用纤溶酶原和尿激酶可以在兔眼中引起玻璃体后脱离。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号